Zelnorm Surgery Incidence Halved Via Novartis/FDA Adjudication
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Re-analysis of surgical cases in clinical trials for Novartis’ constipation-predominant irritable bowel syndrome therapy Zelnorm reduced the incidence of the events by more than half, FDA review documents indicate.
You may also be interested in...
Zelnorm Chronic Constipation Claim Could Increase Target Market By 50%
Novartis’ upcoming sNDA for a Zelnorm chronic constipation indication could increase the potential patient population for the drug by roughly 50%.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product